
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
A preview at what to expect from Dermatology Times this week.
Some of the content the staff at Dermatology Times will be publishing this week includes:
Content on Cash Balance plans;
A brand new edition of The Mainstream Patient;
Exclusive video interviews with KOLs;
Plus more!






